Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI

Last updated: October 20, 2023
Sponsor: Assiut University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes Prevention

Treatment

Pembrolizumab

Clinical Study ID

NCT06100796
ICI outcomes in NSCLC with DM
  • All Genders

Study Summary

Retrospectively investigating the effect of DM on response rate and outcomes during immunotherapy treatment in patients with NSCLC in the last 5 years.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All consecutive patients with advanced Non Small Cell Lung Cancer who received ImmuneCheck Inhibitors alone or in combination with chemotherapy, either as first line or asa subsequent line

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Pembrolizumab
Phase:
Study Start date:
October 01, 2023
Estimated Completion Date:
December 31, 2024

Study Description

Lung cancer continues to be the most common cause of cancer-related death worldwide for both males and females despite the identification of clinically-actionable driver mutations in genomic subgroups of patients. Non-small cell lung cancer (NSCLC) is the most common histological diagnosis for 85% of lung cancer patients. Immune checkpoint inhibitors (ICI) has significantly altered the prognosis for patients with advanced non-small cell lung cancer (mNSCLC) as it has been shown to have distinct and long-lasting impacts on survival in first and second line treatment. As a result, immunotherapy has emerged as the backbone of care for people with NSCLC. Although some patients benefit considerably from ICI, not all patients do. A comprehensive research effort exists to identify and characterize variables that could predict or boost the response to ICI.

At the same time, diabetes mellitus (DM) is becoming more prevalent globally and lung cancer patients frequently suffer from a variety of comorbidities, including (DM). However, its effect on treatment outcomes is still unclear, particularly in the era of immunotherapy.

Connect with a study center

  • Assiut university

    Assiut, 71515
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.